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The Tat protein of the human immunodeficiency virus type 1 promotes survival and growth and inhibits apoptosis of
different cell types. These effects of Tat are attributed to the induction of bcl-2 gene expression. In this study we show that
the blocking of both intracellular and extracellular Tat correlates with a decrease of bcl-2 transcripts, leading in vitro to a
lower growth rate and attenuation of the transformed phenotype and in vivo to a reduced angiogenic and oncogenic activity
of Tat-expressing cells. These results support the notion that bcl-2 is an effector of Tat-induced angiogenesis and
oncogenesis and indicate that the blocking of Tat functions by immunoprophylactic, pharmacological, and gene therapy© 200
tive RTIntroduction. The Tat protein of the human immunode-
ficiency virus type 1 (HIV-1) is an early gene product
essential for virus gene expression and replication (2,
15). Tat promotes transcription of the viral genome by
interacting with the trans-activation responsive (TAR) el-
ement, located at the 5 end of all viral mRNAs (17, 26).
Tat is released into the culture medium in a biologically
active form by either HIV-1-infected or tat-transfected
cells in the absence of cell death (7, 14) and displays
pleiotropic activities on survival and growth of different
cell types (5, 13, 21, 33). In extracellular form and as a
recombinant molecule, Tat shows angiogenic activity
and stimulates adhesion, migration, and invasion of spin-
dle-shaped cells derived from AIDS Kaposi’s sarcoma
(KS) lesions and of normal endothelial cells activated by
inflammatory cytokines (1, 3). In addition, extracellular Tat
behaves as an autocrine and paracrine growth factor
protecting epithelial, lymphoid, and neuronal cells from
apoptosis induced by serum starvation (5, 33). The ef-
fects of Tat on cell survival and growth have been cor-
related with an increased expression of cellular genes
encoding transforming growth factor-1, tumor necrosis
1 To whom correspondence and reprint requests should be ad-
dressed at the Department of Experimental and Diagnostic Medicine,1factor-, interleukin-2, and interleukin-6 (4, 27, 31, 32) or
with modulation of expression of cellular genes involved
in the control of the cell cycle and apoptosis such as p53
(19) and bcl-2 genes (30, 34, 35).
bcl-2 belongs to a gene family encoding proteins that
inhibit (bcl-2, Bcl-xL, Bcl-w, Bfl-1, and Mcl-1) or promote
(Bax, Bad, Bak, Bcl-X, Bid, and Hrk) apoptosis (18). Tat
upregulates bcl-2 gene expression both in Jurkat cells
and in PBMC (34). In addition, it was shown that Tat
activates bcl-2 promoter-directed gene expression and
that either N- or C-terminal sequences of Tat are re-
quired for optimal transactivation (30). In the present
study we have analyzed whether inhibition of intracellu-
lar and extracellular Tat induces down-modulation of
bcl-2 gene expression and consequently reduction or
inhibition of the oncogenic and angiogenic effects of Tat.
Results and Discussion: Generation of cells express-
ing the antisense tat gene. The aim of this study is to
determine whether the blocking of Tat activity reduces or
inhibits the oncogenic and angiogenic effects of cells
expressing Tat. T53 cells are derived from an adenocar-
cinoma of a tat transgenic mouse and constitutively ex-
press and release Tat protein in the culture medium (10,
11). T206 cells, which are also derived from an adeno-
carcinoma of a tat transgenic mouse and harbor the tatapproaches may help to control oncogenesis during AIDS.
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gene, are negative for Tat expression (11) (Table 1). T53
and T206 cells were transfected with a plasmid contain-
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ing the full-length HIV-1 tat cDNA in antisense orientation
(tatAS) and the neo gene as the selectable marker. Sev-
eral clones, obtained from T53 and T206 cell cultures,
were selected and propagated in a culture medium con-
taining geneticin (200 g/ml). Three of these clones
(T53AScl2, T53AScl4, and T206AScl2) were studied in
detail. The Tat protein was detected in cells by flow
cytometry (Fig. 1). Quantitative analysis indicated that the
mean number of Tat molecules per cell was 2200 in T53
cells, 700 in T53AScl2, 600 in T53AScl3, 400 in T53AScl4,
and 550 in T53AScl6 cells (Table 1). Since similar values
were observed in six other T53AS clones, where the
number of Tat molecules ranged between 400 and 700
per cell, these results indicate that transfection of a tat
cDNA in antisense orientation in T53 cells consistently
reduced, but did not completely abrogate, Tat expres-
sion. Indeed, T53AScl2 cells were able to survive without
signs of apoptosis in serum-free medium like T53 cells
(Figs. 2A and 2D), even though at a lower growth rate
(doubling time 53 h) compared to T53 cells (doubling
time 32 h), suggesting that Tat is still released in the
culture medium in amounts sufficient to inhibit apopto-
sis. In fact, an identical apoptotic process was triggered
in T53AScl2 and T53 cells (Figs. 2B, 2C, 2E, and 2F),
when they were treated with an anti-Tat antibody or with
PNU153429, a distamycin A derivative which binds ex-
tracellular Tat and neutralizes its functions (12). We also
evaluated the apoptotic death by flow cytometry. Treat-
ment with an anti-Tat polyclonal antibody induced
apoptosis, indicated by the appearance of a subdiploid
peak, in 37.0% of T53 cells and 27.5% of T53AScl2 cells,
compared to a value of 7.5% (P  0.00001) and 10.0%
(P  0.00001), respectively, in untreated cells (Figs. 3A
and 3B).
We then analyzed the in vitro growth characteristics of
T53AScl2 and T53AScl4 cells. These cells display lower
saturation density and clonogenic activity on plastic and
higher serum dependence than T53 cells (data not
shown). In addition, T53AScl2 cells produced signifi-
cantly lower amounts of urokinase-type plasminogen ac-
tivator (3.2 mU/g protein) than T53 cells (11 mU/g
protein). These results indicate that the block of Tat
correlates with a reduced transformation phenotype in
vitro.
Determination of oncogenicity and angiogenesis. To
assay whether inhibition of Tat expression reduces on-
cogenicity, T53AScl2 and T53AScl4 cells were inoculated
subcutaneously in nude mice. T53 cells were included
as a control. As shown in Table 2, all animals developed
tumors with a short latency period (2–6 days). Thirty days
after cell inoculation, mice were sacrificed to measure
the tumor volume and to determine the presence of
metastases. This analysis indicated that the volume of
tumors induced by T53AScl2 and T53AScl4 cells was
significantly smaller than that of tumors induced by T53
cells (P  0.001 and P  0.01, respectively). Moreover,
four of six animals inoculated with T53 cells developed a
total of 33 metastases in lungs, lymph nodes, kidneys,
and heart, whereas T53AScl2 and T53AScl4 cell clones
produced 2 and 11 metastases, respectively, in two of
four animals (P  0.0005 and P  0.05). The extent of
neoangiogenesis in tumors was analyzed in a separate
experiment as described under Materials and Methods.
The results indicate that the number of capillaries was
significantly lower in tumors induced by T53AScl2 and
T53AScl4 cells than in tumors induced by T53 cells (P 
0.001) (Table 2). Moreover, histologic analysis of tumors
induced by T53AScl2 cells showed the presence of sev-
eral necrotic areas which were absent in tumors induced
by T53 cells. These data indicate that the inhibition of Tat
expression reduces tumorigenicity and angiogenic activ-
ity of T53AS clones, thus leading to a decreased growth
and metastatic dissemination of tumors.
Quantitative analysis of bcl-2 transcripts. Since several
data indicate that Tat protects cells from apoptosis
through activation of bcl-2 gene expression (30, 34) and
FIG. 1. Detection of Tat protein by flow cytometry. Exponentially
growing cells were analyzed as described under Materials and Meth-
ods. (1) Negative control represented by T53 cells treated with a
nonspecific primary mouse monoclonal antibody; (2) T53AScl4 cells; (3)
T53AScl2 cells; (4) T53 cells. Samples 2, 3, and 4 were treated with a
primary mouse anti-Tat monoclonal antibody.
TABLE 1
Quantitative Determination of Tat Protein
Cell lines Tat molecules per cell
T53 2200
T53AScl2 700
T53AScl3 600
T53AScl4 400
T53AScl6 550
T206 0
T206AScl2 0
pRPca 0
Note. Cells were analyzed by flow cytometry and the quantitative
analysis was carried out as described under Materials and Methods.
a Mouse cells immortalized by BK virus early region, not harboring
the tat gene and used as negative control.
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that bcl-2 is oncogenic (29) and angiogenic in vitro and in
vivo (23, 24), we determined whether inhibition of Tat
correlates with down-regulation of bcl-2. To this purpose
a quantitative reverse transcription polymerase chain
reaction (qRT-PCR) was set up as described under Ma-
terials and Methods. The level of bcl-2 mRNA was mea-
sured in T53AScl2 and T53AScl4 cells at different time
intervals (12, 24, 48, and 72 h) in the presence or ab-
sence of serum and compared to bcl-2 expression in T53
cells. Equal amounts of mouse wild-type (wt) bcl-2 RNA,
equivalent to 105 cells, were retrotranscribed and coam-
plified together with 10,000, 5000, 2500, 1250, 625, and
312 molecules of a deleted bcl-2 RNA competitor. The
PCR products were analyzed on a polyacrylamide gel to
separate the 95-bp wt from the 83-bp deleted bcl-2 frag-
ment (Fig. 4A, lanes 1 to 6). The results of these exper-
iments showed that after 48 h of culture in DMEM-F12
medium with 10% fetal bovine serum (FBS), T53AScl2
cells expressed 2170 copies of bcl-2 transcripts per 105
cells, a value 2.5-fold lower than the number of RNA
copies (5457) detected in T53 cells (data not shown).
When cells were cultured in serum-free medium,
T53AScl2 and T53AScl4 cells expressed 2330 and 2110
copies, respectively, and T53 cells expressed 5256 cop-
ies (2.5-fold more) of bcl-2 transcripts per 105 cells at 48 h
(Fig. 4B). At 48 h of cell culture, T53 cells produced an
amount of bcl-2 transcripts comparable to T53AScl2 and
T53AScl4 cells, when extracellular Tat was blocked by
addition of a Tat antibody or PNU153429 to the culture
medium of T53 cells (Fig. 4B), indicating that the greater
bcl-2 expression of untreated T53 cells at 48 h was
entirely due to the effect of extracellular Tat. The reduc-
tion of bcl-2 transcripts is specifically due to the pres-
FIG. 2. Analysis of apoptosis in T53AScl2 and T53 cells maintained in culture for 48 h in serum-free medium. T53AScl2 and T53 cells were untreated
(A and D) and treated with a rabbit anti-Tat polyclonal antibody (B and E) or PNU153429 (C and F). DAPI staining was carried out as described under
Materials and Methods. Arrows mark apoptotic cells and micronuclei. Magnification, 75.
FIG. 3. Evaluation of apoptotic death by flow cytometry in T53 and
T53AScl2 cells. Cells were cultured in serum-free medium and harvested
at 48 h after the addition of a rabbit anti-Tat polyclonal antibody (Ab). (A)
T53 and T53AScl2 cells were untreated or treated with the anti-Tat anti-
body, respectively. Percentage of apoptotic cells is shown in B. Signifi-
cance of the results was calculated by 2 analysis. Values were T53 Ab
versus T53: P  0.00001; T53AScl2  Ab versus T53AScl2: P  0.00001.
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ence of the AS tat gene in T53AScl2 and T53AScl4 cells,
as shown by the results obtained with T206 cells which
contain the tat gene, but do not express Tat protein. In
fact, both T206 cells and stable clones of T206AS cells,
cultured in serum free-medium, produced from 400 to
500 copies of bcl-2 transcripts per 105 cells (Fig. 4B),
suggesting that the expression of an AS tat gene does
not induce nonspecific alterations in cellular physiology.
The decrease of bcl-2 expression in all cell cultures at
72 h (Fig. 4B) is likely due to T53, T53AScl2, and
T53AScl4 cells reaching confluence and ceasing prolif-
eration, while in T53 cells treated with Tat antibody or
PNU153429 the low value of bcl-2 transcripts is probably
dependent on the progression of the apoptotic process
(Figs. 2E and 2F). In the presence of a similar amount of
bcl-2 RNA, T53AScl2 cells survive (Fig. 2A), whereas T53
cells, under conditions of neutralization of extracellular
Tat by Tat antibody or PNU153429, develop apoptosis
(Figs. 2E and 2F), suggesting that extracellular Tat re-
leased by T53AScl2 cells protects them from apoptosis
by a metabolic pathway independent of bcl-2. This evi-
dence indicates that cell survival and proliferation are sup-
ported by extracellular Tat through multiple mechanisms.
Thus, inhibition of Tat in T53AS cell clones results in a
reduced expression of bcl-2, which may be responsible
for the limited tumor volume, metastasis formation, and
angiogenesis observed in mice injected with the T53AS
cells. These data confirm those of Nor et al. (23, 24)
indicating that bcl-2 is involved in angiogenesis and
suggest that Tat-induced bcl-2 expression may signifi-
cantly contribute to the angiogenic effect of Tat. More-
over, relative to the importance of extracellular Tat in
oncogenesis and angiogenesis, these results confirm
and extend a previous investigation showing that mice
inoculated with T53 cells and treated with PNU153429
developed smaller and less vascularized tumors and a
smaller number of metastases than untreated control
mice (25). The present study supports a contribution of
Tat, through bcl-2 activation, to angiogenesis and onco-
genesis during HIV-1 natural infection. Inhibition of Tat
activity with immunoprophylactic, pharmacological, and
gene therapy approaches may therefore help to prevent
and control tumor development in the course of AIDS.
Materials and Methods: Cell cultures, DNA transfec-
tion, RNA extraction, and DAPI staining of cultured cells.
T53 and T206 cell lines were established from adeno-
carcinomas of skin adnexa of tat transgenic mice, as
TABLE 2
Tumorigenicity of T53, T53AScl2, T53AScl4 Cells and Angiogenesis in Tumors
Cell lines
Tumorigenicity
Angiogenesis
Mice with tumors/
inoculated mice
Tumor volume
(mm3)a
Mice with metastases/
mice with tumors
Total number of
metastasesa,b
Number of capillariesc
Day 13 Day 24 Day 35
T53 6/6 1313 344.2 4/6 33 193.8 42 117.7 21.2 111.6 27.4
T53AScl2 4/4 210 76.4* 2/4 2*** 43.5 9.2* 64.3 13.7* 27.2 8*
T53AScl4 4/4 445 199.3** 2/4 11† 27.5 9.2* 54.7 23.6* NDd
Note. Mice were inoculated subcutaneously with 5  105 cells per animal. Tumors appeared with a latency period of 2 to 6 days. Data show
means  SD and were statistically evaluated by Student’s t test (*P  0.001, **P  0.01).
a Tumor volume and metastases were evaluated in mice sacrificed 30 days after cell inoculation.
b Metastases were located in lymph nodes, lungs, renal glomeruli, and heart. Data were statistically evaluated by 2 analysis (***P 0.0005, †P 0.05).
c In a separate experiment, the number of capillaries was counted in 12 different fields of each tumor at 13, 24, and 35 days after cell inoculation.
d ND, not done.
FIG. 4. Quantification of bcl-2 gene expression by qRT-PCR. (A)
Cytoplasmic RNA, extracted from 105 T53AScl2 cells, after 24 h of
culture in serum-free medium, was subjected to reverse transcription
and amplified together with a known number of molecules of compet-
itor RNA (10,000, 5000, 2500, 1250, 625, and 312, from lane 1 to 6). The
wt (95 bp) and deleted competitor (83 bp) PCR products are indicated
by arrows. In this experiment, 1680 wt bcl-2 mRNA copies were calcu-
lated (20) to be present in T53AScl2 cells. (B) Production of bcl-2 mRNA
by cells after 12, 24, 48, and 72 h of culture in serum-free medium.
Cytoplasmic RNA was extracted from 105 cells. Untreated T53 cells ();
T53 cells treated with an anti-Tat antibody (‚) or PNU153429 (F);
T53AScl2 (Œ) and T53AScl4 ({) cells; T206 () and T206AScl2 (E) cells.
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previously described (10, 11). T53AS and T206AS clones
were obtained after transfection of cells with the plasmid
pRPneo-tat/AS (2.5 g/106 cells), containing HIV-1 tat
cDNA in antisense orientation under control of the SV40
promoter (6). T53AS and T206AS clones were selected
with 200 g/ml of geneticin (G418; Sigma Chemical Co.,
St. Louis, MO). Cells were cultured in DMEM-F12 me-
dium (Gibco BRL, Grand Island, NY) with 10% FBS (Gibco
BRL). DNA transfection was performed on subconfluent
T53 and T206 cells by the calcium phosphate precipita-
tion technique (9, 16). Growth characteristics and plas-
minogen activator activity were carried out as previously
described (10, 11). T53 cells (1  106) were treated in
serum-free medium with rabbit polyclonal anti-Tat IgG (5
g/ml; American Biotechnologies, Cambridge, MA) or
with PNU153429 (5 M; Pharmacia & Upjohn, Milan,
Italy), a new polysulfonated distamycin A derivative (12).
Cells were harvested at 12, 24, 48, and 72 h after addition
of antibodies or PNU153429 and pellets were used for
RNA extraction. Cytoplasmic RNA was extracted using
an RNase mini kit (Qiagen, Santa Clarita, CA) according
to the manufacturer’s protocol. DAPI (4,6-diamidino-2-
phenylindole; Sigma) staining of cultured cells was car-
ried out as described by Collins et al. (8). pRPc cells are
mouse kidney cells transformed by BK virus early region
DNA and were used as a negative control in the evalu-
ation of intracellular Tat protein by flow cytometry.
Detection of Tat protein by flow cytometry. Exponen-
tially growing cells (2  106) were harvested and perme-
abilized with 70% ethanol for 1 h at 4°C. Cytometric
detection of Tat molecules was performed by immuno-
fluorescence using a 1:10 dilution of a mouse anti-Tat
monoclonal antibody (MAb; American Biotechnologies),
followed by a goat anti-mouse IgG covalently linked to
fluorescein (GAM-F1; Becton Dickinson, San Jose, CA).
Staining was performed in 200 l phosphate-buffered
saline containing 1% bovine serum albumin (Sigma), at
4°C for 30 min. Nonspecific fluorescence was assessed
with a nonspecific isotype-matched primary mouse MAb
to cytomegalovirus (DuPont, Boston, MA) followed by
GAM-F1 and with GAM-F1 alone. To quantify cell-asso-
ciated fluorescence, before the assay the FACScan was
calibrated by quantitative fluorescein microbeads (Flow
Cytometry Standard Corp.). A standard curve was con-
structed by plotting the mean fluorescence intensity
against the logarithm of the number of fluorescein mol-
ecules per bead. Samples were run in duplicate. Relative
anti-Tat MAb binding sites per cell were obtained by
dividing the number of fluorescein molecules bound per
cell by the fluorescein-to-protein ratio of the anti-Tat
MAb. All experiments were performed under conditions
of saturation.
Evaluation of apoptosis by flow cytometry. Cells, main-
tained in culture in serum-free medium, were harvested
at 48 h after addition of rabbit anti-Tat polyclonal antibody
or PNU153429 and fixed in cold 70% ethanol at 4°C for
1 h. Flow cytometry studies were performed as de-
scribed previously (22) using 104 cells per sample. Re-
sults were evaluated by 2 analysis.
Oncogenicity in nude mice and evaluation of angio-
genesis. Four- to 8-week-old nude mice (Balb/c-nu/nu)
were inoculated subcutaneously with 5  105 cells per
animal and examined daily for the appearance of tumors.
To evaluate tumor volume and metastases, mice were
sacrificed 30 days after cell inoculation. To estimate the
entity and extent of the vascular network in tumors, in a
separate experiment animals were injected ip, at 13, 24
and 35 days after cell inoculation, with the fluorochrome
Hoechst 33342 and killed after 1 min. Tumors were
removed, frozen in liquid nitrogen, and sectioned at three
different levels, and four fields of each level were ob-
served under a UV microscope to count fluorescent ves-
sels. The Hoechst 33342 vascular staining technique
was used according to Smith et al. (28).
Primers used for mutagenesis and amplification. Three
primers were used for the competitive analysis of mouse
bcl-2 mRNA expression: Bcl3, Bcl4, and Bcl4mod. Bcl3
(24-mer) (5-CACACCTGGATCCAGGATAACGGA-3, for-
ward) maps at the 5 end of exon 1 of the bcl-2 gene; Bcl4
(26-mer) (5-AGAGACAGCCAGGAGAAATCAAACAG-3,
reverse) maps at the 3 end of exon 2; and Bcl4mod
(44-mer) (5-AGAGACAGCCAGGAGAAATCAAACAGAG-
GGCCATATAGTTCCAC-3) maps at the 3 end of exon 2
and was used for mutagenesis. This primer, during the
PCR, generates a 12-bp loop in the single-strand tem-
plate resulting in a deletion of the amplified fragment.
Synthesis of the bcl-2 competitor RNA. PCR-mediated
mutagenesis was used to produce the pBcl-2 plasmid,
containing a bcl-2 deleted copy of the Bcl3–Bcl4 cDNA
fragment. The 95-bp product, obtained after RT-PCR of
total RNA from T53 cells, using the primers Bcl3–Bcl4,
was amplified with the primers Bcl3 and Bcl4mod in
order to obtain a fragment with an internal 12-bp dele-
tion. PCR was performed in a 480 Thermal Cycler (Per-
kin–Elmer Cetus, Foster City, CA) under the following
conditions of amplification: 94°C for 15 s, 35°C for 30 s,
72°C for 1 min for the first 6 cycles; 94°C for 30 s, 60°C
for 30 s, 72°C for 1 min for the following 44 cycles. Final
extension was at 72°C for 15 min. The amplified 83-bp
product, which represents the competitor DNA, was
treated for 1 h at 37°C with 2.5 U of T4 DNA polymerase,
in order to generate a blunt-end fragment, and cloned
into the SrfI site of the phagemid pCR-Script SK() (Strat-
agene, La Jolla, CA), to obtain plasmid pBcl-2. In vitro
mRNA was transcribed from the EcoRI-linearized
pBcl-2 plasmid (1 g) with T3 RNA polymerase (Ribo-
probe System-T3, Promega, Madison, CA) as recom-
mended by the manufacturer. Synthesized RNA was re-
suspended in diethyl pyrocarbonate-treated water and
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aliquots were immediately frozen in dry ice and stored at
80°C. Competitor RNA copy number was exactly quan-
tified by spectrophotometric analysis, gel electrophore-
sis, end-point dilution RT-PCR, and Poisson distribution
analysis of the last dilution giving a positive score. The
sensitivity of RT-PCR was equivalent to retrotranscription
of two copies of competitor RNA, as evaluated by spec-
trophotometric analysis.
Quantitative RT-PCR. For qRT-PCR, a known number of
competitor RNA copies (diluted twofold from 10,000 to
312) and a constant amount of wild-type bcl-2 RNA (cor-
responding to 105 cells) were simultaneously subjected
to reverse transcription, using the cDNA Cycle kit (In-
vitrogen Corp., San Diego, CA) in the presence of 20
pmol of Bcl4 antisense primer (final volume 20 l). The
resulting cDNA was amplified with 30 pmol of Bcl4 and
50 pmol of Bcl3 primers in a 9600 Thermal Cycler (Per-
kin–Elmer) using the following conditions of amplifica-
tion: 50 cycles at 95°C for 15 s, 60°C for 15 s, 72°C for
10 s (with an increase of 1 s per cycle in the third step)
and a final incubation at 72°C for 15 min. The amplified
products were analyzed on 10% polyacrylamide minigels
at 180 V for 45 min for optimal separation of the 95-bp
bcl-2 wt fragment from the 83-bp bcl-2 deleted fragment.
After ethidium bromide staining, fluorescent bands were
scanned using a video densitometer (Bio-Rad Laborato-
ries, Hercules, CA) and the RNA copy number was cal-
culated as described by Menzo et al. (20).
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